• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Fulvestrant

Fulvestrant

Product ID F8147
Cas No. 129453-61-8
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $71.50 In stock
25 mg $204.30 In stock
100 mg $612.70 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Fulvestrant is an anti-endocrine compound that exhibits anticancer chemotherapeutic benefit in the treatment of estrogen receptor (ER)-positive breast cancer. Fulvestrant causes degradation of ERs and downregulates ER expression, inhibiting cell growth. Fulvestrant also upregulates expression of UDP glucoronosyltransferase 1A4 (UGT1A4) in cancer cells. Additionally, fulvestrant exhibits some anti-hyperlipidemic benefit in clinical settings, as patients receiving it as a chemotherapeutic also exhibited lower serum levels of total cholesterol and LDL.

Product Info

Cas No.

129453-61-8

Purity

≥98%

Formula

C32H47F5O3S

Formula Wt.

606.77

Chemical Name

(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol

IUPAC Name

(7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5, 5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16, 17-decahydrocyclopenta[a]phenanthrene-3,17-diol

Synonym

Faslodex

Solubility

Soluble in ethanol (>200 mg/mL), DMSO (>20 mg/mL). Insoluble in water. DMF 20 mg/mL, chloroform.

Appearance

White to off white powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

F8147 MSDS PDF

Info Sheet

F8147 Info Sheet PDF

References

Edavana VK, Penney RB, Yao-Borengasser A, et al. Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism. Springerplus. 2013 Nov 20;2:620. PMID: 24298433.

Krell J, Januszewski A, Yan K, et al. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther. 2011 Nov;11(11):1641-52. PMID: 22050013.

Scott SM, Brown M, Come SE. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf. 2011 Sep;10(5):819-26. PMID: 21699443

Camerini A, Rondini M, Garrone O, et al. Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone-receptor-positive metastatic breast cancer patients. Cancer Biol Ther. 2009 Aug;8(15):1450-5. PMID: 19556864.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • A5070

    Angiotensin Acetate

    Peptide, derivative of AT I, cleavage product o...

    ≥95%
  • L3455

    α-Linolenic Acid

    An omega-3 fatty acid.

    ≥98%
  • L8277

    [Gln8]-Luteinizing Hormone Releasing Hormone, chicken

    Endogenous peptide hormone, involved in secreti...

    ≥95%
  • V9202

    VX-702

    p38 MAPK inhibitor.

    ≥98%
  • B0245

    Balicatib

    Cathepsin K inhibitor.

    ≥98%
  • R3476

    RITA

    p53 activator.

    ≥98%
  • N1894

    Nexturastat A

    HDAC6 inhibitor.

    ≥98%
  • I5992

    IOX2

    Prolyl hydroxylase inhibitor.

    ≥98%
  • A744789

    ASTX660

    Antitumor

    ≥98%
  • T1675

    Teriparatide Acetate

    Synthetic peptide hormone, PTH analog; PTH1R ag...

    ≥95%
  • C0248

    Calcineurin Substrate

    Peptide used to measure in vitro calcineurin ac...

    ≥96%
  • R5700

    Ro 61-8048

    Kynurenine 3-hydroxylase inhibitor.

    ≥99%
  • M4452

    MLN2480

    Raf inhibitor.

    ≥98%
  • B0397

    BAY80-6946 Hydrochloride

    pan-PI3K inhibitor

    ≥98%
  • A4930

    7-Aminoactinomycin D

    Actinomycin derivative used to study apoptosis ...

    ≥98%
  • A5278

    Angiotensin III, human

    Endogenous peptide, cleavage product of AT II; ...

    ≥95%
  • B3573

    Bisdemethoxycurcumin

    Curcumin derivative; DNMT1 and α-amylase inhib...

    ≥98%
  • T9946

    Tylosin Phosphate

    Macrolide; peptidyl transferase inhibitor, prot...

    ≥90%
  • C016481

    Camalexin

    Phytoalexin

    ≥98%
  • P2816

    S-(N-3-Phenylpropylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only